cGAS Inhibitor Compounds With Selective Interferon Pathway Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases and cancer metastasis, such as systemic lupus erythematosus and inflammatory bowel disease, are inadequate due to the lack of specific inhibitors for the cGAS pathway, leading to debilitating side effects and ineffective suppression of undesired type I interferon activity.
Innovation Solution
Development of tri-cyclyl nitrogen-containing heterocyclic compounds that act as potent and specific inhibitors of human cGAS, targeting interferon-producing cell types to inhibit inflammatory responses and cancer metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If quinacrine is used as a cGAS inhibitor, then interferon activity is suppressed, but off-target effects occur through interference with RIG-I pathway
Solution Approach 1:
The patent introduces tri-cyclyl nitrogen-containing heterocyclic compounds as specific intermediaries that selectively bind to cGAS active site, preventing direct interaction between dsDNA and cGAS without interfering with RIG-I pathway. These compounds serve as precise mediators that target only the desired enzyme-c substrate interaction.
Solution Approach 2:
The patent modifies the chemical structure parameters by designing tri-cyclyl nitrogen-containing heterocyclic compounds with specific molecular features (Formula I structure with varying R1-R7 substituents) that optimize binding affinity to cGAS while maintaining selectivity. This structural parameter optimization ensures specific inhibition without off-target effects.
2Object-generated harmful factors
If current treatments for autoimmune diseases are used, then inflammatory responses are suppressed, but debilitating side effects occur due to lack of pathway specificity
Solution Approach 1:
The tri-cyclyl nitrogen-containing heterocyclic compounds act as specific intermediaries that selectively inhibit cGAS-mediated type I interferon production without affecting other immune pathways. This targeted mediation suppresses autoinflammatory responses while avoiding the debilitating side effects associated with non-specific immunosuppression.
Solution Approach 2:
The patent applies local quality by designing compounds with specific molecular characteristics (Formula I structure) that confer selective binding to cGAS active site. This localized specificity ensures that only the cGAS pathway is inhibited, leaving other immune functions intact and avoiding systemic side effects.
3Object-generated harmful factors
If cGAS is inhibited to prevent autoinflammatory diseases, then type I interferon activity is reduced, but cancer metastasis surveillance may be affected
Solution Approach 1:
The patent employs partial action by using tri-cyclyl nitrogen-containing heterocyclic compounds that selectively inhibit cGAS activity in specific contexts (autoinflammatory conditions) without completely abolishing cGAS function. This partial inhibition is sufficient to reduce pathological type I interferon activity while preserving enough cGAS activity to maintain cancer surveillance through alternative DNA sensing pathways.
Data Source
AI summary
Tri-cyclyl nitrogen-containing heterocyclic compoundsare disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.